Rescue Medication

Phase 2

Merck & Co.

Rescue Medication is one of 167 therapeutic programs targeting Bladder Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

166

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bladder CancerRecruiting

Ovarian Cancer RecurrentRecruiting

Esophageal Squamous Cell CarcinomaRecruiting

Colorectal CancerRecruiting

Oesophageal Squamous Cell CarcinomaRecruiting

Castration Resistant Prostatic CancerRecruiting

Non Muscle Invasive Bladder CancerRecruiting

Malignant NeoplasmRecruiting

Bladder CancerPreclinical

Recruiting

Ovarian Cancer RecurrentPreclinical

Recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Colorectal CancerPreclinical

Recruiting

Oesophageal Squamous Cell CarcinomaPreclinical

Recruiting

Castration Resistant Prostatic CancerPreclinical

Recruiting

Non Muscle Invasive Bladder CancerPreclinical

Recruiting

Malignant NeoplasmPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 2

Acetylsalicylic Acid

Bayer

Phase 3

7 3

Telisotuzumab Adizutecan

AbbVie

Phase 3

2 4

TAS 102

Taiho Oncology, Inc.

Phase 3

8 5

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

4 6

Cytokine-Induced Killer Cells

TThe First People's Hospital of Changzhou

Phase 3

2 7

Adjuvant Chemotherapy

NNizhny Novgorod Regional Clinical Oncology Center

Phase 3

2 8

Biological Check-up

UUniversity Hospital, Bordeaux

Phase 3

1 9

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 10

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Study completion

NCT07697625

Q2 2028

PreclinicalRecruiting

Oesophageal Squamous Cell Carcinoma

NCT07405151

Q1 2029

PreclinicalRecruiting

Non Muscle Invasive Bladder Cancer

NCT06637423

Q4 2029

PreclinicalRecruiting

Colorectal Cancer

NCT06428409

Clinical

Trials by Indication[1]

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06863272·360 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07405151·60 enrolled

11 more indications

Prostate Cancer1 trial

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06925737·1,440 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·605 enrolled

Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

Malignant Neoplasm1 trial

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07252739·140 enrolled

Bladder Cancer1 trial

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07232602·55 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Unspecified1 trial

A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07697625·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Rescue Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rescue Medication. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Merck & Co.

Rescue Medication

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Q1 2029

Q4 2029

Trials by Indication[1]

Lung Neoplasm1 trial

Diffuse Large B-Cell Lymphoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

Castration Resistant Prostatic Cancer1 trial

Oesophageal Squamous Cell Carcinoma1 trial

Prostate Cancer1 trial

Colorectal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Lymphoma, Large B-Cell, Diffuse1 trial

Triple Negative Breast Neoplasms1 trial

Ovarian Cancer Recurrent1 trial

Breast Neoplasms1 trial

Malignant Neoplasm1 trial

Bladder Cancer1 trial

Non Muscle Invasive Bladder Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News